# Portfolio-level configuration for multi-study management
portfolio:
  program_id: "COMPOUND-X-ONCOLOGY"
  program_name: "Compound X Development Program"
  therapeutic_area: "Oncology"
  indication: "Non-Small Cell Lung Cancer"
  compound: "Compound-X"
  
studies:
  STUDY001:
    study_id: "CX-NSCLC-301"
    protocol_number: "CX-301"
    phase: "Phase III"
    design: "Randomized, Double-Blind, Placebo-Controlled"
    enrollment_target: 850
    countries: 12
    status: "Active - Database Lock Pending"
    database_lock_planned: "2025-03-15"
    database_lock_actual: ""
    primary_endpoint: "Overall Survival"
    priority: 1  # Regulatory submission critical path
    
    team:
      trial_programmer: "Your Name"
      lead_statistician: "Dr. Stats Lead"
      biostatistician: "Stats Support"
      data_manager: "DM Lead"
      medical_monitor: "Dr. Clinical"
    
    milestones:
      protocol_finalization: "2023-06-01"
      first_patient_in: "2023-09-15"
      last_patient_in: "2024-11-30"
      interim_analysis_1: "2024-08-15"
      database_lock: "2025-03-15"
      nda_submission_target: "2025-06-30"
    
    data_sources:
      edc_system: "Medidata Rave"
      sdtm_version: "SDTM 1.7"
      adam_version: "ADaM 1.1"
      cdisc_ct_version: "2023-12-15"
    
    deliverables:
      - type: "Interim Analysis"
        deadline: "2024-08-15"
        status: "Complete"
      - type: "Final Analysis"
        deadline: "2025-04-30"
        status: "In Progress"
      - type: "NDA Submission Package"
        deadline: "2025-06-30"
        status: "Planned"
  
  STUDY002:
    study_id: "CX-NSCLC-201"
    protocol_number: "CX-201"
    phase: "Phase II"
    design: "Single-Arm, Open-Label"
    enrollment_target: 120
    countries: 5
    status: "Active - Enrollment Complete"
    database_lock_planned: "2025-05-01"
    primary_endpoint: "Objective Response Rate"
    priority: 2  # Supports pooled safety
    
    team:
      trial_programmer: "Your Name"
      lead_statistician: "Dr. Stats Lead"
      biostatistician: "Junior Stats"
      data_manager: "DM Support"
    
    milestones:
      first_patient_in: "2024-01-10"
      last_patient_in: "2024-12-15"
      database_lock: "2025-05-01"
    
    data_sources:
      edc_system: "Medidata Rave"
      sdtm_version: "SDTM 1.7"
      adam_version: "ADaM 1.1"
      cdisc_ct_version: "2023-12-15"
  
  STUDY003:
    study_id: "CX-NSCLC-101"
    protocol_number: "CX-101"
    phase: "Phase I"
    design: "Dose-Escalation"
    enrollment_target: 45
    countries: 1
    status: "Complete"
    database_lock_actual: "2024-06-30"
    primary_endpoint: "Maximum Tolerated Dose"
    priority: 3  # Historical, supports ISS
    
    team:
      trial_programmer: "External CRO"
      cro_vendor: "GlobalCRO Inc"
      lead_statistician: "Dr. Stats Lead"
    
    data_sources:
      edc_system: "OpenClinica"
      sdtm_version: "SDTM 1.5"  # Legacy version
      adam_version: "ADaM 1.0"
      cdisc_ct_version: "2021-06-25"

pooled_analyses:
  ISS:
    name: "Integrated Summary of Safety"
    description: "Pooled safety analysis across Phase I-III"
    included_studies: ["STUDY001", "STUDY002", "STUDY003"]
    total_patients: 1015
    analysis_deadline: "2025-05-15"
    primary_datasets: ["ADSL", "ADAE", "ADLB", "ADVS"]
    challenges:
      - "Harmonize SDTM 1.5 vs 1.7 across studies"
      - "Different AE coding dictionaries (MedDRA v23 vs v26)"
  
  ISE:
    name: "Integrated Summary of Efficacy"
    description: "Pooled efficacy for NSCLC indication"
    included_studies: ["STUDY001", "STUDY002"]
    total_patients: 970
    analysis_deadline: "2025-04-30"
    primary_datasets: ["ADSL", "ADRS", "ADTTE"]

resource_allocation:
  programmers:
    - name: "Your Name"
      role: "Senior Statistical Programmer / Portfolio Lead"
      allocation:
        STUDY001: 60  # percent
        STUDY002: 30
        pooled_ISS: 10
    - name: "Junior Programmer A"
      role: "Statistical Programmer"
      allocation:
        STUDY002: 50
        STUDY001_TLF: 50
    - name: "External CRO"
      role: "Vendor Support"
      allocation:
        STUDY003: 100
